General Information of Drug (ID: DM3Z07E)

Drug Name
TP-1287 Drug Info
Synonyms UNII-7MPP85IIJ3; 7MPP85IIJ3; CHEMBL4594423; SCHEMBL18251861; 2044686-42-0; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methyl-4-piperidinyl)-7-(phosphonooxy)-
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
124083048
CAS Number
CAS 2044686-42-0
TTD Drug ID
DM3Z07E

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cyclin-dependent kinase 9 (CDK9) DTT CDK9 5.597 5.711 5.221 5.776
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cyclin-dependent kinase 9 (CDK9) DTT CDK9 4.38E-01 -0.04 -0.1
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03604783) Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.